Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response
If you need an accessible version of this item, please email your request to digschol@iu.edu so that they may create one and provide it to you.
Date
2023-01-03
Language
American English
Embargo Lift Date
Department
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
Wiley
Abstract
Here we present a case of metastatic PNET which arose from an immature teratoma that was refractory to standard Ewing sarcoma chemotherapy. This PNET was determined to have elevated levels of ALK protein via IHC. The patient was treated with crizotinib on a palliative basis with a sustained response.
Description
Keywords
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Snyder BM, Lion AH, Helvie AE, Marshall MS, Ferguson MJ. Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response. Clin Case Rep. 2023;11(1):e6779. Published 2023 Jan 3. doi:10.1002/ccr3.6779
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Clinical Case Reports
Source
PMC
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Permanent Link
Version
Final published version